Literature DB >> 32323584

Clinical significance of increased PML-RARa transcripts after induction therapy for acute promyelocytic leukaemia.

Mi Liang1, Lei Wang1, Min Xiao1, Jie Xiong1, Jin Wang1, Zhiqiong Wang1, Wei Huang1, Jianfeng Zhou1.   

Abstract

Objective: To analyze the clinical and biological significance of the acute promyelocytic leukemia (APL) whose PML-RARa transcripts increased after induction therapy.
Methods: We analyzed 9 cases of APL whose PML-RARa transcripts increased after induction treatment and compare them with APL whose PML-RARa transcripts decreased.
Results: The only factor affecting increased PML-RARa transcripts was the induction protocol. The cases of increased PML-RARa transcripts received induction treatment mainly based on ATRA and ATO. The evaluation of bone marrow aspirate cytology showed that the cell percentage from myelocyte to segmented neutrophil of the patients with increased PML-RARa transcripts was significantly higher than that of the patients with decreased PML-RARa transcripts. In the follow-up, MRD in 9 cases was consistently negative.Conclusions: Our studies showed the increased PML-RARa transcripts after induction treatment had different clinical significance from the decreased PML-RARa transcripts.

Entities:  

Keywords:  Bone marrow aspirate cytology; PML-RARa transcripts; acute promyelocytic leukaemia; induction treatment

Mesh:

Substances:

Year:  2020        PMID: 32323584      PMCID: PMC7877940          DOI: 10.1080/07853890.2020.1753886

Source DB:  PubMed          Journal:  Ann Med        ISSN: 0785-3890            Impact factor:   4.709


  22 in total

1.  Role of minimal residual disease monitoring in acute promyelocytic leukemia treated with arsenic trioxide in frontline therapy.

Authors:  Ezhilarasi Chendamarai; Poonkuzhali Balasubramanian; Biju George; Auro Viswabandya; Aby Abraham; Rayaz Ahmed; Ansu Abu Alex; Saravanan Ganesan; Kavitha M Lakshmi; Usha Sitaram; Sukesh Chandran Nair; Mammen Chandy; Nancy Beryl Janet; Vivi M Srivastava; Alok Srivastava; Vikram Mathews
Journal:  Blood       Date:  2012-02-28       Impact factor: 22.113

2.  Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial.

Authors:  A K Burnett; D Grimwade; E Solomon; K Wheatley; A H Goldstone
Journal:  Blood       Date:  1999-06-15       Impact factor: 22.113

3.  Using quantification of the PML-RARalpha transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia.

Authors:  Carlos Santamaría; Maria Carmen Chillón; Carina Fernández; Patricia Martín-Jiménez; Ana Balanzategui; Ramón García Sanz; Jesús F San Miguel; Marcos-Gonzalez González
Journal:  Haematologica       Date:  2007-03       Impact factor: 9.941

4.  Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells.

Authors:  G Q Chen; X G Shi; W Tang; S M Xiong; J Zhu; X Cai; Z G Han; J H Ni; G Y Shi; P M Jia; M M Liu; K L He; C Niu; J Ma; P Zhang; T D Zhang; P Paul; T Naoe; K Kitamura; W Miller; S Waxman; Z Y Wang; H de The; S J Chen; Z Chen
Journal:  Blood       Date:  1997-05-01       Impact factor: 22.113

5.  Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience.

Authors:  Lionel Adès; Agnes Guerci; Emmanuel Raffoux; Miguel Sanz; Patrice Chevallier; Simona Lapusan; Christian Recher; Xavier Thomas; Consuelo Rayon; Sylvie Castaigne; Olivier Tournilhac; Stephane de Botton; Norbert Ifrah; Jean-Yves Cahn; Eric Solary; Claude Gardin; Nathalie Fegeux; Dominique Bordessoule; Augustin Ferrant; Sandrine Meyer-Monard; Norbert Vey; Herve Dombret; Laurent Degos; Sylvie Chevret; Pierre Fenaux
Journal:  Blood       Date:  2009-12-17       Impact factor: 22.113

6.  Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. GIMEMA-AIEOP Multicenter "AIDA" Trial.

Authors:  D Diverio; V Rossi; G Avvisati; S De Santis; A Pistilli; F Pane; G Saglio; G Martinelli; M C Petti; A Santoro; P G Pelicci; F Mandelli; A Biondi; F Lo Coco
Journal:  Blood       Date:  1998-08-01       Impact factor: 22.113

7.  Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia.

Authors:  M E Huang; Y C Ye; S R Chen; J R Chai; J X Lu; L Zhoa; L J Gu; Z Y Wang
Journal:  Blood       Date:  1988-08       Impact factor: 22.113

8.  Absence of reverse transcription-polymerase chain reaction detectable residual disease in patients with acute promyelocytic leukemia in long-term remission.

Authors:  D Diverio; P P Pandolfi; A Biondi; G Avvisati; M C Petti; F Mandelli; G Pelicci; F Lo Coco
Journal:  Blood       Date:  1993-12-15       Impact factor: 22.113

9.  Expression pattern of the RAR alpha-PML fusion gene in acute promyelocytic leukemia.

Authors:  M Alcalay; D Zangrilli; M Fagioli; P P Pandolfi; A Mencarelli; F Lo Coco; A Biondi; F Grignani; P G Pelicci
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

10.  All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia.

Authors:  Zhi-Xiang Shen; Zhan-Zhong Shi; Jing Fang; Bai-Wei Gu; Jun-Min Li; Yong-Mei Zhu; Jing-Yi Shi; Pei-Zheng Zheng; Hua Yan; Yuan-Fang Liu; Yu Chen; Yang Shen; Wen Wu; Wei Tang; Samuel Waxman; Hugues De Thé; Zhen-Yi Wang; Sai-Juan Chen; Zhu Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-24       Impact factor: 11.205

View more
  1 in total

Review 1.  Cytogenetics analysis as the central point of genetic testing in acute myeloid leukemia (AML): a laboratory perspective for clinical applications.

Authors:  Aliaa Arina Rosli; Adam Azlan; Yaashini Rajasegaran; Yee Yik Mot; Olaf Heidenreich; Narazah Mohd Yusoff; Emmanuel Jairaj Moses
Journal:  Clin Exp Med       Date:  2022-10-13       Impact factor: 5.057

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.